DK3630726T3 - Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse - Google Patents

Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK3630726T3
DK3630726T3 DK18732548.5T DK18732548T DK3630726T3 DK 3630726 T3 DK3630726 T3 DK 3630726T3 DK 18732548 T DK18732548 T DK 18732548T DK 3630726 T3 DK3630726 T3 DK 3630726T3
Authority
DK
Denmark
Prior art keywords
crystallinic
dimethoxyquinolin
dicarboxamide
cyclopropane
fluorophenyl
Prior art date
Application number
DK18732548.5T
Other languages
Danish (da)
English (en)
Inventor
Khalid Shah
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62683441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3630726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of DK3630726T3 publication Critical patent/DK3630726T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DK18732548.5T 2017-05-26 2018-05-26 Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse DK3630726T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511714P 2017-05-26 2017-05-26
PCT/US2018/034784 WO2018218233A1 (en) 2017-05-26 2018-05-26 Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Publications (1)

Publication Number Publication Date
DK3630726T3 true DK3630726T3 (da) 2022-03-07

Family

ID=62683441

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18732548.5T DK3630726T3 (da) 2017-05-26 2018-05-26 Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse

Country Status (20)

Country Link
US (3) US11279675B2 (OSRAM)
EP (1) EP3630726B1 (OSRAM)
JP (3) JP7166292B2 (OSRAM)
KR (1) KR102611445B1 (OSRAM)
CN (1) CN110621662B (OSRAM)
AU (1) AU2018272088C1 (OSRAM)
CA (1) CA3060370A1 (OSRAM)
DK (1) DK3630726T3 (OSRAM)
EA (1) EA039654B1 (OSRAM)
ES (1) ES2909390T3 (OSRAM)
HU (1) HUE058196T2 (OSRAM)
IL (1) IL270780B2 (OSRAM)
MA (1) MA48776A (OSRAM)
MX (1) MX2019012505A (OSRAM)
PL (1) PL3630726T3 (OSRAM)
PT (1) PT3630726T (OSRAM)
SG (1) SG11201909161PA (OSRAM)
UA (1) UA127760C2 (OSRAM)
WO (1) WO2018218233A1 (OSRAM)
ZA (1) ZA201906127B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939546C (en) * 2014-02-14 2023-01-17 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EA039654B1 (ru) * 2017-05-26 2022-02-22 Экселиксис, Инк. Кристаллические твердые формы солей n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и методы использования
CA3088200A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
TWI770624B (zh) 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途
JP7509779B2 (ja) 2018-12-13 2024-07-02 エグゼリクシス, インコーポレイテッド キナーゼ阻害剤の結晶性形態及び塩形態
CA3139148A1 (en) * 2019-06-03 2020-12-10 Exelixis, Inc. Crystalline salt forms of a kinase inhibitor
CA3245315A1 (en) 2022-03-01 2023-09-07 Synthon B.V. L(+) TARTARIC ACID CABOZANTINIB SALT AND ITS SOLID FORMS
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
CA2758030C (en) * 2009-01-16 2019-01-08 Exelixis, Inc. Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
TWI619495B (zh) 2010-07-16 2018-04-01 艾克塞里克斯公司 C-met調節劑醫藥組合物
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
CA2826751C (en) * 2011-02-10 2021-05-18 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
KR20140069133A (ko) 2011-09-22 2014-06-09 엑셀리시스, 인코포레이티드 골다공증의 치료방법
US9535315B2 (en) 2011-10-31 2017-01-03 Applied Materials, Inc. Method of fabricating a color filter array using a multilevel structure
JP2015505360A (ja) 2011-11-08 2015-02-19 エクセリクシス, インク. 癌治療を定量化する方法
MX2014005458A (es) 2011-11-08 2015-04-16 Exelixis Inc Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer.
CN104649969B (zh) 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
CA2939546C (en) * 2014-02-14 2023-01-17 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EP3145913A1 (en) * 2014-05-23 2017-03-29 Mylan Laboratories Ltd. Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base
CN104961680B (zh) 2014-11-07 2017-09-12 苏州晶云药物科技有限公司 N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型
CN104961681B (zh) 2014-11-13 2017-06-13 苏州晶云药物科技有限公司 卡博替尼的粘酸盐及其晶型
EP3274333B1 (en) * 2015-03-25 2019-04-24 Sandoz AG Cabozantinib salts and their use as anti-cancer agents
ES2716633T3 (es) 2015-03-25 2019-06-13 Sandoz Ag Formas cristalinas de fosfato de cabozantinib e hidrocloruro de cabozantinib
US10980792B2 (en) * 2016-09-12 2021-04-20 Zhuhai Beihai Biotech Co., Ltd. Formulations of Cabozantinib
EP3551612A4 (en) * 2016-12-07 2020-08-12 MSN Laboratories Private Limited, R&D Center PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE
EA039654B1 (ru) * 2017-05-26 2022-02-22 Экселиксис, Инк. Кристаллические твердые формы солей n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и методы использования

Also Published As

Publication number Publication date
AU2018272088A1 (en) 2019-10-17
JP7437460B2 (ja) 2024-02-22
CA3060370A1 (en) 2018-11-29
PL3630726T3 (pl) 2022-05-09
CN110621662B (zh) 2023-06-23
JP7659097B2 (ja) 2025-04-08
WO2018218233A1 (en) 2018-11-29
JP2020521732A (ja) 2020-07-27
US20220162166A1 (en) 2022-05-26
EP3630726A1 (en) 2020-04-08
EA201992803A1 (ru) 2020-04-16
MA48776A (fr) 2020-04-08
JP2022145852A (ja) 2022-10-04
MX2019012505A (es) 2019-12-19
UA127760C2 (uk) 2023-12-27
NZ757564A (en) 2025-05-02
HUE058196T2 (hu) 2022-07-28
EA039654B1 (ru) 2022-02-22
US12227481B2 (en) 2025-02-18
AU2018272088A8 (en) 2019-10-24
US20210261509A1 (en) 2021-08-26
AU2018272088B2 (en) 2022-06-16
US20240010621A1 (en) 2024-01-11
IL270780B1 (en) 2024-12-01
IL270780B2 (en) 2025-04-01
US11731941B2 (en) 2023-08-22
ZA201906127B (en) 2022-11-30
US11279675B2 (en) 2022-03-22
ES2909390T3 (es) 2022-05-06
IL270780A (en) 2020-01-30
JP7166292B2 (ja) 2022-11-07
CN110621662A (zh) 2019-12-27
SG11201909161PA (en) 2019-10-30
AU2018272088C1 (en) 2022-09-22
PT3630726T (pt) 2022-03-02
KR102611445B1 (ko) 2023-12-06
EP3630726B1 (en) 2021-12-22
JP2024036690A (ja) 2024-03-15
KR20200010205A (ko) 2020-01-30

Similar Documents

Publication Publication Date Title
DK3630726T3 (da) Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse
ZA201605424B (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
EA201591756A1 (ru) Метаболиты n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида
SI3713919T1 (sl) Kristalinične oblike n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil) fenil)kinolin-8-sulfonamida
EA201891742A1 (ru) Замещенное пиперидиновое соединение и его применение
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
EP3536698A4 (en) LANOSTEROLPRODRUG COMPOUND AND MANUFACTURING METHOD THEREFOR AND USE THEREOF
UA122528C2 (uk) Сполуки, які модулюють fxr (nr1h4)
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EP3723752A4 (en) NEW SOLID FORMS OF CANNABIDIOL AND USES OF IT
EA201692356A1 (ru) Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида
EP3572409A4 (en) 1,3,5-TRIAZINE DERIVATIVE SALT, CRYSTAL, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EA201891644A1 (ru) Антибактериальные соединения и их применение
MA44672A (fr) Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
JOP20170100B1 (ar) توليف مركبات إندازول
EA201890570A1 (ru) [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
HUE063043T2 (hu) Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
DK3752497T3 (da) P300/cbp-hat-hæmmere
EA201992259A1 (ru) Замещенные n-(1,3,4-оксадиазол-2-ил)арилкарбоксамиды и их применение в качестве гербицидов
EP3594216A4 (en) FIVE-PIECE HETEROCYCLIC AMINOPYRIMIDINE COMPOUND AND INTERMEDIATE PRODUCT, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
EP3639845C0 (en) Il-15 protein complex pharmaceutical composition and uses thereof
EA201990158A1 (ru) Производные бензодиоксана и их фармацевтическое применение
EP3419988A4 (en) NEW PRNA TRIPLE CONNECTIONS
EA201991595A1 (ru) Активатор nrf2